PREVOZNIK MICHAEL E

SVP General Counsel Prevoznik sold 3,878 DGX shares at $206.21 on 2026-03-05; retains 37,557 shares.

Michael Prevoznik, SVP & General Counsel, sold 3,878 shares (9.4% of pre-transaction holdings) at $206.21, reducing his stake from 41,435 to 37,557 shares. The sale occurred at a price $6.00 above the current $199.21 close and within 5% of the 52-week high of $211.91, consistent with timing near recent strength. Across his five prior DGX trades, Prevoznik's timing outcomes have been mixed: two were well-timed at the 90-day mark (negative returns), but three showed positive 90-day returns after the sale, indicating the stock often rose following his exits. His cross-ticker track record shows a 28.57% well-timed sell rate with average 90-day returns of +2.8%, suggesting limited predictive consistency. Quest Diagnostics remains operationally sound with $2.8B quarterly revenue, +11.8% annual growth, and a 20.08 P/E, and the SVP retains a substantial position of 37,557 shares, indicating continuing alignment with the company.

SVP & General Counsel Michael E Prevoznik sold 28,463 shares of DGX for $5,326,041.82 near 52-week highs.

Michael E Prevoznik, SVP & General Counsel, executed 2 separate sales totaling 28,463 shares for $5,326,041.82 on 2025-09-23 and 2025-09-24 at an average price of $187.12. This sale reduced his holdings by 42.8%, from 66,580 to 38,117 shares. The transaction occurred when DGX was trading at $185.39, approximately -0.8% from its 52-week high of $186.97, near the upper end of its annual range. His prior 5 sales at DGX over the past year all showed positive 90-day returns (+5.2% to +9.8%), meaning the stock rose after each sale—a pattern indicating his recent sales have been poorly timed relative to subsequent price appreciation. At a blended average price of $187.12, this latest sale was executed slightly above the current price, reflecting recent momentum (+2.8% over 30 days, +4.2% over 90 days).

SVP & General Counsel Michael Prevoznik sold 4,643 shares of DGX at $170.00 for $789,310.00 on 2025-03-17

Michael Prevoznik sold 4,643 shares representing 10.9% of his pre-transaction holdings at $170.00, reducing his stake from 42,760 to 38,117 shares. The sale occurred near the 52-week high (current price $168.01 is only 5.0% below the $176.95 peak), and historically his four prior sales at DGX posted an average 90-day return of +5.5%, indicating the stock typically rose after his prior exits at this ticker. His cross-ticker track record shows a 0.00% well-timed rate on sales, suggesting his prior open-market sales across all holdings have not demonstrated predictive value for downturns. The fundamentals remain solid with revenue at $2,488,000,000, net income at $226,000,000, and annual growth of 6.7%, providing no obvious distress signal.

SVP & General Counsel Michael E. Prevoznik sold 35,146 shares at average $163.07 for $5.7M (47.7% of holdings)

Michael E. Prevoznik executed 2 separate sales on 2024-11-29, totaling 35,146 shares for $5,731,301.51, at prices of $162.26 and $163.15—near the 52-week high of $163.89. The sale reduced his holdings by 47.7%, from 73,624 to 38,478 shares. His prior 2 sales at DGX occurred on 2024-08-29 (30d -0.1%, 90d +5.4%) and 2024-02-29 (30d +5.7%, 90d +9.8%), with both followed by subsequent price appreciation at the 90-day mark—neither was well-timed. The latest sale comes as the stock sits at $161.51 (−1.4% from 52-week high, +4.0% over 30 days), and follows a pattern in which his prior DGX sales yielded positive 90-day returns for shareholders, indicating consistent exit timing that did not precede material declines.

SVP & General Counsel Michael E Prevoznik sold 32,551 shares of DGX at $154.97 for $5.0M, reducing stake to 38.5K.

Michael E Prevoznik, serving as SVP & General Counsel, sold 32,551 shares for $5,044,516.36 on 2024-08-29, a significant 45.8% reduction in his personal holdings at Quest Diagnostics. The transaction occurred at $154.97, just below the current price of $156.97, which itself sits at the 52-week high. His prior sale at the same ticker on 2024-02-29 generated positive 90-day returns (+9.8%), indicating his recent sells have not preceded price declines; across his open-market history, the 90d well-timed rate stands at 0.00%, suggesting a pattern of selling into strength rather than ahead of weakness. With annual revenue contracting 6.4% and the company trading at a P/E of 20.79, the substantial disposal by a senior legal officer warrants investor attention to any underlying business headwinds.